MEI Pharma, Inc.

As of July 8, 2024, MEI Pharma, Inc. is considered overvalued with poor financial metrics, including a Price to Book Value of 0.74, an EV to EBITDA ratio of 0.27, a ROE of -106.26%, and significant underperformance compared to the S&P 500, making it a less attractive investment.

As of November 12, 2024, MEI Pharma, Inc. has shifted from an attractive to a non-qualifying valuation grade, indicating it is overvalued with concerning financial ratios and underperformance compared to peers and the S&P 500.

As of May 9, 2025, MEI Pharma, Inc. shows a mildly bearish trend, influenced by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals from the MACD and KST.

As of March 2022, the management team of MEI Pharma, Inc. includes Dr. Christine White (Independent Chairman), Dr. Daniel Gold (President and CEO), and five Independent Directors: Mr. Charles Baltic, Dr. Kevan Clemens, Ms. Cheryl Cohen, and Mr. Frederick Driscoll.

MEI Pharma, Inc. is an oncology company focused on developing cancer treatments, categorized as a micro-cap with a market cap of $14.99 million. As of March 2025, it reported a net profit loss of $3 million and has no dividend yield.

As of Jun 18, MEI Pharma, Inc. has a market capitalization of 14.99 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -31.67 million for the latest four quarters. The company reported shareholder's funds of 33.02 million and total assets of 41.38 million as of Jun'24.